BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmacology - ECPv6.11.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:/pharm
X-WR-CALDESC:Events for Pharmacology
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250325T160000
DTEND;TZID=America/New_York:20250325T170000
DTSTAMP:20250428T133314
CREATED:20250310T204042Z
LAST-MODIFIED:20250310T204133Z
UID:10001000-1742918400-1742922000@www.med.unc.edu
SUMMARY:Dr. Megan Agajanian of Stanford presents
DESCRIPTION:Megan Agajanian\, PhD\nPostdoctoral Scholar\, Roel Nuuse Lab\nDepartment of Developmental Biology\nStanford University \nSeminar title: “The dynamic role of TBX3 in “The dynamic role of TBX3 in cancer and development” \nLocation: 1131 Bioinformatics \nPlease join us and show support for our seminar speakers!\n(For those unable to attend\, a zoom link is available upon request to Mimi Baltz.) \nHost: Mike Emanuele \nMegan is a postdoc in Roul Nouse’s lab\, the person who first identified Wnt signaling in humans. She is a former Pharmacology student in the Emanuele Lab.  She has been funded by HHMI Gilliam and a K00 Award\, and was selected for the NSF-ASCB FRED Program. \nDr. Agajanian is interested in lineage plasticity and the signals that drive diverse cellular responses. Her postdoctoral work focuses on the dynamic role of TBX3 in breast cancer and mammary gland development. TBX3 mutations in the developing embryo result in Ulnar Mammary Syndrome\, which is characterized by incomplete mammary gland development. In contrast\, TBX3 is mutated in breast cancer and is associated with metastasis. Despite these critical roles of TBX3\, the role of patient mutations in breast cancer progression and the role of TBX3 in postnatal mammary gland expansion remain virtually unstudied. Using organoid and mouse models\, we have demonstrated TBX3 supports organoid growth and in vivo is required for mammary gland expansion during puberty. Interestingly\, previous work identified TBX3 as a lineage specific component of the Wnt transcriptional complex in colorectal cancer\, but it’s role in Wnt signaling in the mammary gland remains unknown. With her background in Wnt signaling interrogation\, in the future\, she aims to pursue her interest in lineage and context dependent regulators of this critical signaling cascade using a wide array of techniques\, including organoid models\, molecular biology\, proteomic\, and in vivo approaches. \n“My project focuses on TBX3 (T-Box Transcription Factor 3)\, one of the top ten mutated genes in breast cancer. TBX3 upregulation and loss of function mutations are identified in patients\, raising the question: is TBX3 a proto-oncogene or tumor suppressor? My work in the Nusse lab will define the role of TBX3 in breast cancer progression and identify TBX3 targets that can be utilized as therapeutic targets in TBX3-associated breast cancer.” ~ https://nusselab.stanford.edu/people/megan-agajanian/ \nFlyer [pdf]
URL:/pharm/event/dr-megan-agajanian-of-stanford-presents/
LOCATION:1131 Bioinformatics\, 130 Mason Farm Rd\, Chapel Hill\, North Carolina\, 27514\, United States
CATEGORIES:Pharmacology Seminars
ATTACH;FMTTYPE=image/jpeg:/pharm/wp-content/uploads/sites/930/2025/01/megan-agajanian-250.jpg
ORGANIZER;CN="Mimi Baltz":MAILTO:my.le@unc.edu
END:VEVENT
END:VCALENDAR